RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Fifth Affiliated Hospital of Sun Yat-sen University; 5 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 6

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fifth Affiliated Hospital of Sun Yat-sen University中山大学附属第五医院ZhuhaiHospital page
  2. Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
  3. Study siteBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page
  4. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  5. Study siteGansu Provincial Cancer Hospital甘肃省肿瘤医院LanzhouHospital page
  6. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06760039, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed DLBCL

    Inclusion criterion 2

  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-

    Inclusion criterion 5

  4. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.

    Inclusion criterion 4

  5. Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.

    Exclusion criterion 5

  6. Pregnant and lactating women and subjects of childbearing age who do not want to use contraception.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06760039, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Inclusion Criteria:

  • Aged ≥18,≤80 years, both male and female.
  • Pathologically confirmed DLBCL
  • No prior treatment for DLBCL.
  • There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-
  • Expected survival ≥3 months.
  • International Prognostic Index (IPI) ≤ 2
  • Sufficient bone marrow, liver, and kidney function.

Key Exclusion Criteria:

  • Other types of LBCL:Primary Cutaneous Diffuse Large B-cell Lymphoma (Leg Type), Primary Mediastinal (Thymic) Large B-cell Lymphoma, Lymphomatoid Granulomatosis, ALK-positive Diffuse Large B-cell Lymphoma, Plasmablastic Lymphoma, Intravascular Large B-cell Lymphoma, T-cell/Histiocyte-rich Large B-cell Lymphoma, and others.
  • Transformed DLBCL.
  • Patients with central nervous system involvement, or those who require high-dose methotrexate for prevention.
  • The patients had previously received antitumor therapy.
  • Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.
  • Pregnant and lactating women and subjects of childbearing age who do not want to use contraception.
  • Mentally ill persons or persons unable to obtain informed consent.
  • The investigators think that the patient is not suitable for the study.

Quoted from ClinicalTrials.gov, NCT06760039, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06760039, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06760039